Sugi Predict

Sugi Predict / Compounds / SCHEMBL490066

SCHEMBL490066

SCHEMBL490066

O=C(N1CCc2ccc(S(=O)(=O)Cl)cc2C1)C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 5/20 0.65
▸ ESR2 Q92731 5/20 0.65
▸ PKM P14618 1/20 0.61
▸ CA1 P00915 4/20 0.47
▸ CA2 P00918 4/20 0.47
▸ CA7 P43166 4/20 0.47
▸ CA9 Q16790 4/20 0.47
▸ CA12 O43570 1/20 0.47
▸ ABHD6 Q9BV23 4/20 0.44
▸ CA14 Q9ULX7 3/20 0.41
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ NR1H2 P55055 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30408119 1.00 ESR1 (0.65) ESR1ESR2PKMCA1CA2
SCHEMBL6436222 0.95 ESR2 (0.65) ESR1ESR2PKMCA1CA2
SCHEMBL30471045 0.95 ESR2 (0.65) ESR1ESR2PKMCA1CA2
SCHEMBL7838175 0.92 ESR1 (0.55) ESR1ESR2PKMCA1CA2
SCHEMBL3899192 0.92 ESR1 (0.53) ESR1ESR2PKMCA1CA2
SCHEMBL2993408 0.89 ESR1 (0.68) ESR1ESR2PKMCA1CA2
SCHEMBL15399197 0.89 ESR1 (0.49) ESR1ESR2PKMCA1CA2
SCHEMBL11477876 0.88 ESR1 (0.67) ESR1ESR2PKMCA1CA2
SCHEMBL20681402 0.87 ESR1 (0.65) ESR1ESR2PKMCA1CA2
SCHEMBL8277232 0.87 ESR1 (0.65) ESR1ESR2PKMCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556064-B1 Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide SANOFI SA (FR) 2014-10-15 — — EP claimed
US-8748615-B2 Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide SANOFI (FR) 2014-06-10 — — US claimed
US-20130123302-A1 PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE SANOFI (FR) 2013-05-16 — — US claimed
EP-2556064-A2 PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE SANOFI (FR) 2013-02-13 — — EP claimed
WO-2011109680-A2 PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE SANOFI (FR) 2011-09-09 — — WO claimed
US-20250136552-A1 ANTAGONISTS OF CAV 2.3 LARIO THERAPEUTICS LIMITED (GB) 2025-05-01 — — US disclosed
US-20250101003-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2025-03-27 — — US disclosed
EP-4436661-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS Lario Therapeutics Limited (GB) 2024-10-02 — — EP disclosed
EP-4436664-A1 ANTAGONISTS OF CAV 2.3 Lario Therapeutics Limited (GB) 2024-10-02 — — EP disclosed
WO-2023094828-A1 ANTAGONISTS OF CAV 2.3 LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 — — WO disclosed
WO-2023094828-A1 ANTAGONISTS OF CAV 2.3 LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 — — WO disclosed
WO-2023094827-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 — — WO disclosed
EP-0822187-A1 PYRAZOLE DERIVATIVES AND HERBICIDES NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1998-02-04 — — EP disclosed
EP-0728132-B1 ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES PFIZER LTD (GB) 1997-07-16 — — EP disclosed
WO-1996038471-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER INC. (US) 1996-12-05 — — WO disclosed
WO-1996035713-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER, INC. (US) 1996-11-14 — — WO disclosed
WO-1996033993-A1 ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) 1996-10-31 — — WO disclosed
EP-0728132-A1 ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES PFIZER LTD (GB) 1996-08-28 — — EP disclosed
WO-1995013274-A1 ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES PFIZER LIMITED (GB) 1995-05-18 — — WO disclosed
US-4228170-A INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE SMITHKLINE CORPORATION (US) 1980-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101003-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS CACNA1A, CACNA1E, CACNA1S ESR1 3920/4885ESR2 1259/4885PKM 1951/4885
US-20250136552-A1 ANTAGONISTS OF CAV 2.3 CACNA1E, CACNA1A, CACNA1S ESR1 4309/4885ESR2 2687/4885PKM 2942/4885
US-20130123302-A1 PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE SULT1E1, SULT2A1, STS ESR1 4308/4885ESR2 3345/4885PKM 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.